A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms

PURPOSE: Treatment options are limited in patients with metastatic neuroendocrine neoplasms (NEN). We present the results for a phase II trial of combination nivolumab and temozolomide in patients with advanced NEN along with results of immune changes in peripheral blood. PATIENTS AND METHODS: NCT03...

Descripción completa

Detalles Bibliográficos
Autores principales: Owen, Dwight H., Benner, Brooke, Wei, Lai, Sukrithan, Vineeth, Goyal, Ashima, Zhou, Ye, Pilcher, Carly, Suffren, Sheryl-Ann, Christenson, Gwen, Curtis, Nancy, Jukich, Megan, Schwarz, Emily, Savardekar, Himanshu, Norman, Ruthann, Ferguson, Sarah, Kleiber, Barbara, Wesolowski, Robert, Carson, William E., Otterson, Gregory A., Verschraegen, Claire F., Shah, Manisha H., Konda, Bhavana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932582/
https://www.ncbi.nlm.nih.gov/pubmed/36255391
http://dx.doi.org/10.1158/1078-0432.CCR-22-1552

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932582/
https://www.ncbi.nlm.nih.gov/pubmed/36255391
http://dx.doi.org/10.1158/1078-0432.CCR-22-1552

Ejemplares similares